These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 29398578

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R.
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
    Yano Y, Kurebe H, Edahiro R, Hosono Y, Nakatsubo S, Nishida K, Sawa N, Ishijima M, Uenami T, Kanazu M, Akazawa Y, Yamaguchi T, Mori M.
    PLoS One; 2018 Feb; 13(8):e0203070. PubMed ID: 30153300
    [Abstract] [Full Text] [Related]

  • 8. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
    Figueiredo A, Almeida MA, Almodovar MT, Alves P, Araújo A, Araújo D, Barata F, Barradas L, Barroso A, Brito U, Camacho E, Canário D, Cardoso T, Chaves A, Costa L, Cunha J, Duarte J, Estevinho F, Felizardo M, Fernandes JP, Ferreira L, Ferreira L, Fidalgo P, Freitas C, Garrido P, Gil N, Hasmucrai D, Jesus E, Lopes JA, de Macedo JE, Meleiro A, Neveda R, Nogueira F, Pantorotto M, Parente B, Pego A, Rocha M, Roque J, Santos C, Saraiva J, Silva E, Silva S, Simões S, Soares M, Teixeira E, Timóteo T, Hespanhol V.
    Pulmonology; 2020 Feb; 26(1):10-17. PubMed ID: 31630986
    [Abstract] [Full Text] [Related]

  • 9. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N.
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study.
    Karadurmus N, Kaplan MA, Sendur MAN, Urun Y, Demirci U, Karaca SB, Goktas Aydin S, Aykan MB, Bilici A, Sezer A, Yilmaz U, Abali H, Yumuk PF, Degirmencioglu S, Demirkazik A, Paydas S, Mirili C, Turna H, Kargi A, Ozdogan M, Guven DC, Ozguroglu M, Kilickap S.
    Curr Med Res Opin; 2024 Jul; 40(7):1171-1178. PubMed ID: 38809230
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
    Kim SH, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, Ji W, Lee JC.
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3025-3036. PubMed ID: 32583235
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.
    Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, Baglivo S, Dal Bello MG, Ceribelli A, Grossi F, Chiari R.
    Clin Lung Cancer; 2019 May; 20(3):178-185.e2. PubMed ID: 30910574
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status.
    Adachi Y, Tamiya A, Taniguchi Y, Enomoto T, Azuma K, Kouno S, Inagaki Y, Saijo N, Okishio K, Atagi S.
    Cancer Med; 2020 Feb; 9(4):1383-1391. PubMed ID: 31880861
    [Abstract] [Full Text] [Related]

  • 20. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
    Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F.
    Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.